Ascletis Pharma Inc
HKEX:1672
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.78
1.96
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Ascletis Pharma Inc
Ascletis Pharma Inc
Accounts Payable
Ascletis Pharma Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ascletis Pharma Inc
HKEX:1672
|
Accounts Payable
¥649k
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Accounts Payable
¥3.7B
|
CAGR 3-Years
20%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Accounts Payable
¥308.9m
|
CAGR 3-Years
40%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Accounts Payable
¥299.9m
|
CAGR 3-Years
39%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Accounts Payable
¥1.1B
|
CAGR 3-Years
25%
|
CAGR 5-Years
85%
|
CAGR 10-Years
39%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Accounts Payable
¥16.3B
|
CAGR 3-Years
23%
|
CAGR 5-Years
42%
|
CAGR 10-Years
91%
|
|
Ascletis Pharma Inc
Glance View
Ascletis Pharma, Inc. operates as biotechnology firm to test the waters. The company is headquartered in Hangzhou, Zhejiang and currently employs 266 full-time employees. The company went IPO on 2018-08-01. The firm is focused on three therapeutic areas, including anti-viral, cancer and fatty liver disease. The Company’s main products include drugs against hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
See Also
What is Ascletis Pharma Inc's Accounts Payable?
Accounts Payable
649k
CNY
Based on the financial report for Dec 31, 2023, Ascletis Pharma Inc's Accounts Payable amounts to 649k CNY.
What is Ascletis Pharma Inc's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
-46%
Over the last year, the Accounts Payable growth was -79%. The average annual Accounts Payable growth rates for Ascletis Pharma Inc have been -10% over the past three years , -46% over the past five years .
You don't have any saved screeners yet
